Bone Fracture – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Bone Fracture – Pipeline Review, H2 2017’, provides an overview of the Bone Fracture pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bone Fracture, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bone Fracture and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Bone Fracture

The report reviews pipeline therapeutics for Bone Fracture by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Bone Fracture therapeutics and enlists all their major and minor projects

The report assesses Bone Fracture therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Bone Fracture

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Bone Fracture

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bone Fracture pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

American Gene Technologies International Inc

BiologicsMD Inc

Biopharm GmbH

Bone Therapeutics SA

Cellmid Ltd

Chrysalis BioTherapeutics Inc

Entera Bio Ltd

Escape Therapeutics Inc

ethris GmbH

Kuros Biosciences AG

Laboratorios SALVAT SA

Novartis AG

Pluristem Therapeutics Inc

TissueGene Inc

Viking Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Bone Fracture - Overview 6

Bone Fracture - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 11

Products under Development by Companies 12

Products under Development by Universities/Institutes 14

Bone Fracture - Therapeutics Assessment 15

Assessment by Target 15

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Bone Fracture - Companies Involved in Therapeutics Development 23

American Gene Technologies International Inc 23

BiologicsMD Inc 23

Biopharm GmbH 23

Bone Therapeutics SA 24

Cellmid Ltd 24

Chrysalis BioTherapeutics Inc 25

Entera Bio Ltd 25

Escape Therapeutics Inc 25

ethris GmbH 26

Kuros Biosciences AG 26

Laboratorios SALVAT SA 27

Novartis AG 27

Pluristem Therapeutics Inc 28

TissueGene Inc 28

Viking Therapeutics Inc 29

Bone Fracture - Drug Profiles 30

ALLOB - Drug Profile 30

bimagrumab - Drug Profile 34

BMD-1221 - Drug Profile 37

cannabidiol - Drug Profile 38

Cell Therapy for Non-Union Fractures - Drug Profile 41

Cyndacel-M - Drug Profile 42

denosumab biosimilar - Drug Profile 44

dibotermin alfa biosimilar - Drug Profile 45

Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture - Drug Profile 46

Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders - Drug Profile 47

Gene Therapy for Bone Fracture - Drug Profile 48

Gene Therapy for Bone Fracture - Drug Profile 49

Gene Therapy to Activate BMP2 and VEGF for Bone Fracture - Drug Profile 50

HCSVT-1001 - Drug Profile 51

KAL-436 - Drug Profile 52

KAL-439 - Drug Profile 54

KUR-111 - Drug Profile 55

KUR-113 - Drug Profile 57

LWnt-3a - Drug Profile 59

Monoclonal Antibody to Inhibit Midkine for Bone Fractures - Drug Profile 60

Oligonucleotide to Activate BMP-2 for Bone Fracture - Drug Profile 61

OsteoStem - Drug Profile 62

PLX-PAD - Drug Profile 63

PREOB - Drug Profile 74

Recombinant Peptide to Agonize PTH1R for Bone Fracture - Drug Profile 77

Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile 78

rusalatide acetate - Drug Profile 80

S-008399 - Drug Profile 84

Small Molecules for Metabolic and Musculoskeletal Disorders - Drug Profile 85

Small Molecules for Musculoskeletal and Metabolic Disorders - Drug Profile 86

SPI-86 - Drug Profile 87

Synthetic Peptide for Osteoporosis and Bone Fracture - Drug Profile 88

TG-B - Drug Profile 89

VK-5211 - Drug Profile 90

Bone Fracture - Dormant Projects 93

Bone Fracture - Discontinued Products 94

Bone Fracture - Product Development Milestones 95

Featured News & Press Releases 95

Appendix 106

Methodology 106

Coverage 106

Secondary Research 106

Primary Research 106

Expert Panel Validation 106

Contact Us 106

Disclaimer 107

List of Tables

List of Tables

Number of Products under Development for Bone Fracture, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Bone Fracture – Pipeline by American Gene Technologies International Inc, H2 2017

Bone Fracture – Pipeline by BiologicsMD Inc, H2 2017

Bone Fracture – Pipeline by Biopharm GmbH, H2 2017

Bone Fracture – Pipeline by Bone Therapeutics SA, H2 2017

Bone Fracture – Pipeline by Cellmid Ltd, H2 2017

Bone Fracture – Pipeline by Chrysalis BioTherapeutics Inc, H2 2017

Bone Fracture – Pipeline by Entera Bio Ltd, H2 2017

Bone Fracture – Pipeline by Escape Therapeutics Inc, H2 2017

Bone Fracture – Pipeline by ethris GmbH, H2 2017

Bone Fracture – Pipeline by Kuros Biosciences AG, H2 2017

Bone Fracture – Pipeline by Laboratorios SALVAT SA, H2 2017

Bone Fracture – Pipeline by Novartis AG, H2 2017

Bone Fracture – Pipeline by Pluristem Therapeutics Inc, H2 2017

Bone Fracture – Pipeline by TissueGene Inc, H2 2017

Bone Fracture – Pipeline by Viking Therapeutics Inc, H2 2017

Bone Fracture – Dormant Projects, H2 2017

Bone Fracture – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Bone Fracture, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports